Molecular Oncology
Volume 3, Issue 3 , Pages 220-237 , June 2009

Molecular characterization of apocrine carcinoma of the breast: Validation of an apocrine protein signature in a well-defined cohort

  • Julio E. Celis

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • Corresponding Author InformationCorresponding author. Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark. Tel.: +45 35257363; fax: +45 35257375.
    • ,
  • Teresa Cabezón

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • ,
  • José M.A. Moreira

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • ,
  • Pavel Gromov

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • ,
  • Irina Gromova

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • ,
  • Vera Timmermans-Wielenga

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • Department of Pathology, The Centre of Diagnostic Investigations, Rigshospitalet, Copenhagen, Denmark
    • ,
  • Takuji Iwase

      Affiliations

    • Department of Breast Oncology, Cancer Institute Hospital, Tokyo, Japan
    • ,
  • Futoshi Akiyama

      Affiliations

    • Department of Pathology, Cancer Institute, Tokyo, Japan
    • ,
  • Naoko Honma

      Affiliations

    • Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
    • ,
  • Fritz Rank

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • Department of Pathology, The Centre of Diagnostic Investigations, Rigshospitalet, Copenhagen, Denmark

Received 8 January 2009 ,Revised 23 January 2009 ,Accepted 26 January 2009.

References 

  1. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature. 2003;422:198–207
  2. Aggarwal BB, Sethi G, Baladandayuthapani V, Krishnan S, Shishodia S. Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J. Cell. Biochem. 2007;102:580–592
  3. Agrawal A, Fentiman IS. NSAIDs and breast cancer: a possible prevention and treatment strategy. Int. J. Clin. Pract. 2008;62:444–449
  4. Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat. Cell Biol. 2007;9:201–209
  5. Azzopardi J. Problems in Breast Pathology. Philadelphia, PA: WB Saunders; 1979;pp. 23–87
  6. Ben-Kasus T, Schechter B, Sela M, Yarden Y. Cancer therapeutic antibodies come of age: targeting minimal residual disease. Mol. Oncol. 2007;1:42–54
  7. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–2502
  8. Celis JE, Gromov P. 2D protein electrophoresis: can it be perfected?. Curr. Opin. Biotechnol. 1999;10:16–21
  9. Celis JE, Trentemølle S, Gromov P. Gel-Based proteomics: high-resolution two-dimensional gel electrophoresis of proteins. Isoelectric Focusing (IEF) and Nonequilibrium pH Gradient Electrophoresis (NEPHGE). In:  Celis JE,  Carter N,  Hunter T,  Simons K,  Small JV,  Shotton D editor. third ed.. A Cell Biology. Laboratory Handbook. vol. 4:AP San Diego: Elsevier; 2005;
  10. Celis JE, Gromov P, Moreira JM, Cabezón T, Friis E, Vejborg IM, et al. Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype. Mol. Cell. Proteomics. 2006;5:462–483
  11. Celis JE, Gromova I, Gromov P, Moreira JM, Cabezon T, Friis E, et al. Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. FEBS Lett. 2006;580:2935–2944
  12. Celis JE, Moreira JM, Gromova I, Cabezon T, Gromov P, Shen T, et al. Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. Mol. Oncol. 2007;1:97–119
  13. Celis JE, Gromova I, Cabezon T, Gromov P, Shen T, Timmermans-Wielenga V, et al. Identification of a subset of breast carcinomas characterized by expression of cytokeratin15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. Mol. Oncol. 2007;1:321–349
  14. Celis JE, Gromov P, Cabezón T, Moreira JM, Friis E, Jirström K, et al. 15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma. Mol. Cell. Proteomics. 2008;7:1795–1809
  15. Chautard, E., Thierry-Mieg, N., Ricard-Blum, S. Interaction networks: from protein functions to drug discovery. Pathol. Biol., in press.
  16. Chen EI, Yates JR. Cancer proteomics by quantitative shotgun proteomics. Mol. Oncol. 2007;1:144–159
  17. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006;10:529–541
  18. Cho H, Tai HH. Inhibition of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by cyclooxygenase inhibitors and chemopreventive agents. Prostaglandins Leukot. Essent. Fatty Acids. 2002;67:461–465
  19. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8:235–244
  20. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat. Rev. Cancer. 2005;5:930–942
  21. Ericsson C, Franzén B, Nistér M. Frozen tissue biobanks. Tissue handling, cryopreservation, extraction, and use for proteomic analysis. Acta Oncol. 2006;45:643–661
  22. Eusebi V, Millis RR, Cattani MG, Bussolati G, Azzopardi JG. Apocrine carcinoma of the breast. A morphologic and immunocytochemical study. Am. J. Pathol. 1986;123:532–541
  23. Fadare O, Tavassoli FA. Clinical and pathologic aspects of basal-like breast cancers. Nat. Clin. Pract. Oncol. 2008;5:149–159
  24. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24:4660–4671
  25. Fishman MC, Porter JA. Pharmaceuticals: a new grammar for drug discovery. Nature. 2005;437:491–493
  26. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Bégin LR, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004;64:830–835
  27. Frable WJ, Kay S. Carcinoma of the breast. Histologic and clinical features of apocrine tumors. Cancer. 1968;21:756–763
  28. Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K. Cyclooxygenase-2 (COX-2) in carcinogenesis and selective COX-2 inhibitors for chemoprevention in gastrointestinal cancers. J. Gastrointest. Cancer. 2007;38:78–82
  29. Gatalica Z. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol. Res. Pract. 1997;193:753–758
  30. Gromov P, Celis JE, Gromova I, Rank F, Timmermans-Vilenga V, Moreira JMA. A single lysis solution for the analysis of tissue samples by different proteomic technologies. Mol. Oncol. 2008;2:368–379
  31. Hodgson DR, Whittaker RD, Herath A, Amakye D, Clack G. Biomarkers in oncology drug development. Mol. Oncol. 2009;3(1):24–32
  32. Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, et al. The CD44+/CD24− phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008;10:R53
  33. Honma N, Takubo K, Akiyama F, Sawabe M, Arai T, Younes M, et al. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. Histopathology. 2005;47:195–201
  34. Honma N, Takubo K, Akiyama F, Kasumi F, Sawabe M, Arai T, et al. Expression of oestrogen receptor-beta in apocrine carcinomas of the breast. Histopathology. 2007;50:425–433
  35. Hull MA. Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?. Eur. J. Cancer. 2005;41:1854–1863
  36. Ideker T, Galitski T, Hood L. A new approach to decoding life: systems biology. Annu. Rev. Genomics Hum. Genet. 2001;2:343–372
  37. Irvin WJ, Carey LA. What is triple-negative breast cancer?. Eur. J. Cancer. 2008;44:2799–2805
  38. Japaze H, Emina J, Diaz C, Schwam RJ, Gercovich N, Demonty G, et al. ‘Pure’ invasive apocrine carcinoma of the breast: a new clinicopathological entity?. Breast. 2005;14:3–10
  39. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol. Oncol. 2007;1:84–96
  40. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell. 2006;127:1041–1055
  41. Kristiansen G, Schlüns K, Yongwei Y, Denkert C, Dietel M, Petersen I. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br. J. Cancer. 2003;88:231–236
  42. Krause S, Maffini MV, Soto AM, Sonnenschein C. A novel 3D in vitro culture model to study stromal-epithelial interactions in the mammary gland. Tissue Eng. Part C Methods. 2008;14:261–271
  43. Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Ikdahl T, et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res. 2007;9:R30
  44. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat. Methods. 2007;4:359–365
  45. Levitzki A. Targeting signal transduction for disease therapy. Med. Oncol. 1997;14:83–89
  46. Lim SC, Oh SH. The role of CD24 in various human epithelial neoplasias. Pathol. Res. Pract. 2005;201:479–486
  47. Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum. Pathol. 2007;38:197–204
  48. Marrer E, Dieterle F. Biomarkers in oncology drug development: rescuers or troublemakers?. Expert Opin. Drug Metab. Toxicol. 2008;4:1391–1402
  49. Mazoujian G, Pinkus GS, Davis S, Haagensen DE. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am. J. Pathol. 1983;110:105–112
  50. Miller WR, Shivas AA, Franchimont P, Haagensen DE. Breast gross cystic disease protein 15 in human breast cancer in culture. Eur. J. Cancer Clin. Oncol. 1988;24:223–228
  51. Moinfar F. Is ‘basal-like’ carcinoma of the breast a distinct clinicopathological entity? A critical review with cautionary notes. Pathobiology. 2008;75:119–131
  52. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. 2005;65:7917–7925
  53. Moreira JM, Ohlsson G, Rank FE, Celis JE. Down-regulation of the tumor suppressor protein 14-3-3sigma is a sporadic event in cancer of the breast. Mol. Cell. Proteomics. 2005;4:555–569
  54. Moriya T, Kozuka Y, Kanomata N, Tse GM, Tan PH. The role of immunohistochemistry in the differential diagnosis of breast lesions. Pathology. 2009;41:68–76
  55. Mossler JA, Barton TK, Brinkhous AD, McCarty KS, Moylan JA, McCarty KS. Apocrine differentiation in human mammary carcinoma. Cancer. 1980;46:2463–2471
  56. Murtola TJ, Visakorpi T, Lahtela J, Syvälä H, Tammela TLj. Statins and prostate cancer prevention: where we are now, and future directions. Nat. Clin. Pract. Urol. 2008;5:376–387
  57. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004;10:5367–5374
  58. O'Malley FP, Bane A. An update on apocrine lesions of the breast. Histopathology. 2008;52:3–10
  59. Page DL. Special types of invasive breast cancer, with clinical implications. Am. J. Surg. Pathol. 2003;27:832–835
  60. Page DL. Apocrine carcinomas of the breast. Breast. 2005;14:1–2
  61. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004;351:2817–2826
  62. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752
  63. Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J. Pathol. 2006;208:495–506
  64. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology. 2008;52:108–118
  65. Riegman PHJ, Morente MM, Betsou F, de Blasio P, Geary P. Biobanking for better healthcare. Mol. Oncol. 2008;2:213–222
  66. Rodríguez-Pinilla SM, Sarrió D, Honrado E, Moreno-Bueno G, Hardisson D, Calero F, et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J. Clin. Pathol. 2007;60:1006–1012
  67. Rosen P. Invasive duct carcinoma. Assessment of prognosis, morphologic prognostic markers, and tumor growth rate. In:  Rosen P editors. Rosen's Breast Pathology. second ed.. Philadelphia: Lippincott Williams & Wilkins; 2001;
  68. Sapp M, Malik A, Hanna W. Hormone receptor profile of apocrine lesions of the breast. Breast J. 2003;9:335–356
  69. Selim AG, Wells CA. Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors. J. Clin. Pathol. 1999;52:838–841
  70. Schiess R, Wollscheid B, Aebersold R. Targeted proteomic strategy for clinical biomarker discovery. Mol. Oncol. 2009;3(1):33–44
  71. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 2001;98:10869–10874
  72. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U.S.A. 2003;100:8418–8423
  73. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J. Biol. Chem. 2002;277:18649–18657
  74. Surowiak P, Materna V, Györffy B, Matkowski R, Wojnar A, Maciejczyk A, et al. Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers. Br. J. Cancer. 2006;95:339–346
  75. Tanaka K, Imoto S, Wada N, Sakemura N, Hasebe K. Invasive apocrine carcinoma of the breast: clinicopathologic features of 57 patients. Breast J. 2008;14:164–168
  76. Tavassoli FA, Norris HJ. Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases. Mod. Pathol. 1994;7:813–818
  77. Tavassoli FA, Purcell CA, Bratthauer GL, Man Y. Androgen receptor expression along with loss of Bcl-2, ER, and PR expression in benign and malignant apocrine lesions of the breast: implications of therapy. Breast J. 1996;2:261–269
  78. In:  Tavassoli FA,  Devilee P editor. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003;
  79. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002;347:1999–2009
  80. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536
  81. Wells CA, El-Ayat GA. Non-operative breast pathology: apocrine lesions. J. Clin. Pathol. 2007;60:1313–1320
  82. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol. 2008;216:141–150
  83. Winkler DA. Network models in drug discovery and regenerative medicine. Biotechnol. Annu. Rev. 2008;14:143–170

PII: S1574-7891(09)00021-0

doi: 10.1016/j.molonc.2009.01.005

Molecular Oncology
Volume 3, Issue 3 , Pages 220-237 , June 2009

Article Tools

* Image Usage & Resolution